-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo CEO Says Open to Exploring M&A Opportunities to Fill 'Gaps' in Drug Pipeline

MT Newswires·09/22/2026 06:08:24
Listen to the news
06:08 AM EDT, 09/22/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) could look into mergers and acquisitions to fill "gaps" in its drug pipeline, CNBC reported Tuesday, citing an interview with Chief Executive Officer Mike Doustdar. In an interview, the CEO added that the Wegovy maker is "quite interested" in companies with available or upcoming products that are "better drugs than we are able to do on our own." Doustdar's statement comes after the Danish drugmaker's updated strategy and targets failed to impress investors, sending the company's shares tumbling by as much as 9% on Monday.